Targeting Co-Stimulatory Receptors of the TNF Superfamily for Cancer Immunotherapy

Area of Science:

• Immunology and Oncology
• Cancer Immunotherapy
• Drug Development

Background:

• Immune checkpoint inhibitors represent a significant advancement in cancer immunotherapy.
• Limited patient response rates necessitate combination therapies to improve treatment efficacy.
• Targeting co-stimulatory pathways ('hitting the gas pedal') is an emerging strategy to enhance anti-tumor immunity.

Purpose of the Study:

• To review the development of agonists targeting co-stimulatory receptors within the Tumor Necrosis Factor Superfamily (TNF-SF).
• To discuss recombinant antibody and ligand-based agonists for 4-1BB, OX40, and GITR.
• To provide an overview of current formats, trends, and clinical applications of these agonists.

Main Methods:

• Literature review of recombinant antibody and ligand-based agonists targeting TNF-SF co-stimulatory receptors.
• Analysis of structural and mechanistic challenges associated with TNF-SF modulation.
• Synthesis of data from current clinical studies and development trends.

Main Results:

• Development of various agonist formats (antibody- and ligand-based) for 4-1BB, OX40, and GITR.
• Identification of challenges related to the structural and mechanistic complexities of the TNF-SF.
• Emerging clinical data on the safety and efficacy of these co-stimulatory agonists.

Conclusions:

• Agonists of co-stimulatory receptors (4-1BB, OX40, GITR) are promising additions to cancer immunotherapy strategies.
• Overcoming TNF-SF structural and mechanistic challenges is crucial for successful therapeutic development.
• Combination therapies involving these agonists hold potential to expand patient benefits in cancer treatment.